BiotechTube
AkiraBio

AkiraBio

San Diego, United States· Est.
akirabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $13M

Overview

AkiraBio is a private, preclinical-stage biotech targeting hemoglobinopathies with its lead candidate, AB1. AB1 is an oral, once-daily small molecule designed to induce fetal hemoglobin (HbF) production by inhibiting DNMT1, aiming to act as a 'functional cure' for sickle cell disease and thalassemia. The company is positioned in a high-need market with significant unmet medical need, seeking to develop a convenient, broadly accessible therapy. As a young company, it is pre-revenue and focused on advancing its lead program through clinical development.

HematologyGenetic Disorders

Technology Platform

Oral small molecule epigenetic modulators targeting DNA methyltransferase 1 (DNMT1) to induce fetal hemoglobin (HbF) production.

Funding History

2
Total raised:$13M
Seed$8M
Seed$5M

Opportunities

The high unmet need for convenient, accessible treatments in sickle cell disease and thalassemia creates a large addressable market.
The oral, once-daily profile of AB1 offers a significant potential advantage over complex, invasive, and expensive gene therapies, enabling broader patient access and chronic disease management.

Risk Factors

Major risks include clinical failure of AB1 due to lack of efficacy or safety issues, intense competition from advanced therapeutic modalities like gene editing, and reliance on external financing as a pre-revenue company.
Regulatory hurdles in demonstrating a functional cure claim are also significant.

Competitive Landscape

Competition is intense and evolving. It includes recently approved gene therapies (Casgevy, Lyfgenia), other HbF inducers like hydroxyurea (generic) and voxelotor (Oxbryta), and several gene-editing therapies in development. AkiraBio's differentiation rests on the oral, potentially disease-modifying profile of AB1 aiming for functional cure-level efficacy with superior convenience.

More companies in Small Molecule Drugs →More companies in United States →